Incidence and predictors of no-reflow phenomenon in acute myocardial infarction patients treated with pharmacoinvasive strategy

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

TCTR

Registry ID

TCTR20200601006

Enrollment

Unknown

Registered

2020-06-01

Start date

2018-11-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

no reflow phenomenon in hospital occurrence of death cardiogenic shock recurrent myocardial infarction bleeding no reflow acute myocardial infarction pharmacoinvasive strategy post balloon dilation

Interventions

STEMI patients who received pharmacoinvasive strategy

Screening

Pharmacoinvasive

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: patients who were diagnosed ST-segment elevation myocardial infarction (STEMI)

Exclusion criteria

Exclusion criteria: patients who underwent coronary angiography (CAG) but did not receive coronary interventions and patients whom the coronary angiogram was missing.

Design outcomes

Primary

Measure	Time frame
Incidence of no reflow periprocedure percentage	—

Secondary

Measure	Time frame
in-hospital occurrence of death, cardiogenic shock, recurrent myocardial infarction and bleeding. in-hospital admission percentage	—

Countries

Thailand

Contacts

Public ContactPannipa Suwannasom

Chiang Mai University

pannipa.s@cmu.ac.th053934453

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Incidence and predictors of no&#45;reflow phenomenon in acute myocardial infarction patients treated with pharmacoinvasive strategy